Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps

[In The News]

EAST HANOVER, N.J., Dec. 11, 2019 /PRNewswire/ -- The submission is based on positive results from the Phase III POLYP 1 and POLYP 2 studies of Xolair in adults with chronic rhinosinusitis with nasal polyps with inadequate response to intranasal corticosteroids If approved, Xolair would...

View the full article